교아종 치료 시장 : 치료, 약제 클래스별, 제형별, 성별, 최종 용도별 - 세계 예측(2024-2032년)

Global Glioblastoma Multiforme Treatment Market size will record 8.6% CAGR from 2024 to 2032, due to increasing partnerships among research institutions along with advancements in medical research.

The ongoing collaborative efforts are leading to the development of innovative therapies and improving existing treatments to address the challenges of the aggressive brain tumor. Researchers are also working together to combine resources and expertise, leading to more effective approaches in managing glioblastoma. For instance, in February 2023, argTex partnered with IAG to apply AI in evaluating the effects of a novel clinical candidate for glioblastoma multiforme patients to enhance treatment assessment and advance therapeutic options for the challenging brain tumor.

The market is segregated into treatment, drug class, dosage form, gender, end-use, and region.

In terms of treatment, the chemotherapy segment in the glioblastoma multiforme treatment industry is set to experience growth at a significant rate through 2032. This is due to the rising prominence of chemotherapy in targeting the dividing cancer cells to slow the tumor growth. Ongoing research is helping in optimizing chemotherapy regimens to enhance effectiveness and minimize side effects. Increasing efforts are directed towards developing more targeted drugs and combining chemotherapy with other treatments like radiation and immunotherapy to achieve better patient outcomes and extend survival rates.

By gender, the glioblastoma multiforme treatment market value from the female segment is projected to rise from 2024 to 2032, fueled by the increasing need to address the specific needs of female patients while considering gender differences in disease progression and treatment response. Ongoing research is focusing on how glioblastoma affects women uniquely and tailoring therapies accordingly. Moreover, treatment plans are integrated with targeted therapies and personalized approaches to improve outcomes for female patients.

Regionally, the Europe glioblastoma multiforme treatment industry size is projected to depict robust growth between 2024 and 2032, driven by increasing funding for cancer research along with supportive government and regulatory initiatives. Research teams are utilizing additional funding to explore new treatment approaches and enhance existing therapies. Governments and regulatory bodies are providing resources and streamlined processes to accelerate the development of innovative treatments. The combined impacts of the supportive measures will transform the approach to treating this aggressive brain tumor across Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of glioblastoma
    • 3.2.1.2 Rising awareness and early diagnosis of disease
    • 3.2.1.3 Increase in the number of R&D activities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High recurrence rate of glioblastoma even after treatment
    • 3.2.2.2 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Surgery
• 5.3 Radiation therapy
• 5.4 Chemotherapy
• 5.5 Targeted therapy
• 5.6 Tumor treating field therapy
• 5.7 Immunotherapy

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Temozolomide
• 6.3 Bevacizumab
• 6.4 Lomustine
• 6.5 Carmustine wafers

Chapter 7 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Male
• 8.3 Female

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Cancer treatment centers
• 9.4 Ambulatory surgical centers
• 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Amgen Inc.
• 11.2 Amneal Pharmaceuticals
• 11.3 Curtana Pharmaceuticals
• 11.4 Denovo Biopharma
• 11.5 Eisai Co. Ltd. (Gliadel)
• 11.6 F. Hoffmann La Roche Ltd (Genetech USA)
• 11.7 Karyopharm Therapeutics
• 11.8 Merck & Co. Inc.
• 11.9 Novocure GmbH
• 11.10 Pfizer, Inc.
• 11.11 Sumitomo Dainippon Pharma Co., Ltd.
• 11.12 Sun Pharmaceutical Industries Ltd.
• 11.13 Teva Pharmaceutical Industries